No menu items!

Brazil’s ANVISA suspends analysis of Indian vaccine Covaxin for lack of essential documents

RIO DE JANEIRO, BRAZIL - Brazil's National Health Regulatory Agency (ANVISA) extended on Wednesday, June 30, the deadline to complete its analysis of the application for emergency use of the Indian vaccine against Covid-19 Covaxin, because of the absence of mandatory and documents essential for the evaluation of the efficacy and safety of the vaccine, the regulator said.

The vaccine is at the center of the Covid CPI investigation in the Brazilian Senate for alleged irregularities during negotiations.

ANVISA said in an official statement that it had notified Precisa Medicamentos, the author of the application, to provide the outstanding . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?

Check out our other content